Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
Treatments studied
Part of Cancer clinical trials.
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had HER2+ breast cancer that was stage T1c-T3 and N0-N1 (except T3N1) before treatment.
- After chemotherapy and trastuzumab, there was no cancer left in the breast or lymph nodes (except for a type of non-invasive cell called DCIS).
- You received at least 12 weeks of trastuzumab with chemotherapy before surgery.
- You are 18 years or older and have a good general health status (ECOG 0-2).
- You had surgery to remove all visible cancer, and you either had a mastectomy or lumpectomy with clear margins.
- You are registering within 14 weeks of your final surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
This trial tests whether giving Herceptin for a shorter time after chemotherapy works as well as the usual longer treatment for early-stage HER2-positive breast cancer. It aims to reduce side effects and treatment burden while keeping the same benefits.
This trial compares two different treatments for women with HER2-positive early breast cancer who had a complete response to initial therapy but still have cancer DNA in their blood. It aims to see which treatment is better at preventing the cancer from coming back.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This trial tests if giving two HER2-targeted drugs together works as well when one is injected under the skin as when it is given through an IV. It aims to find a more convenient option for early-stage breast cancer patients.
This study looks at different treatment plans after surgery for people with HER2-positive breast cancer who still have cancer cells remaining after initial chemo and trastuzumab. It aims to see which approach helps improve outcomes.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.